Since CCL2/CCR2 signaling is a central signaling pathway that promotes monocyte recruitment into the TME, CCR2 inhibitors eliminate TAMs and inhibit tumor proliferation [91,92]. This evidence concerns the gene CCL2 and neoplasm.